Patents by Inventor Allan E. Karlsen

Allan E. Karlsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diabetes-mediating proteins and therapeutic uses thereof
    Patent number: 7531323
    Abstract: Provided are protective and deleterious diabetes-mediating proteins and polynucleotides encoding same, transgenic animals expressing a diabetes-mediating protein, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein.
    Type: Grant
    Filed: July 18, 2006
    Date of Patent: May 12, 2009
    Inventors: Peter Mose Larsen, Stephen J. Fey, Jorn Nerup, Allan E. Karlsen, Ulla Bjerre Christensen, Flemming Pociot, Henrik U. Andersen
  • Human diabetes-mediating proteins
    Patent number: 7521193
    Abstract: Determining the expression level of certain diabetes-mediating proteins provides an approach both for diagnosing diabetes and for ascertaining a predisposition for developing diabetes.
    Type: Grant
    Filed: March 20, 2003
    Date of Patent: April 21, 2009
    Assignee: Pride Proteomics A/S
    Inventors: Peter Mose Larsen, Stephen J. Fey, Jørn Nerup, Allan E. Karlsen
  • METHOD FOR DIAGNOSING DIABETES IN A MAMMAL
    Publication number: 20080145868
    Abstract: Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of the expression of a diabetes-mediating protein.
    Type: Application
    Filed: October 9, 2007
    Publication date: June 19, 2008
    Applicant: PRIDE PROTEOMICS A/S
    Inventors: Peter Mose Larsen, Stephen J. Fey, Allan E. Karlsen, Thomas Sparre, Jorn Nerup
  • Method for diagnosing diabetes in a mammal
    Patent number: 7279274
    Abstract: Provided are mammalian secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of the expression of a diabetes-mediating protein.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: October 9, 2007
    Assignee: Pride Proteomics A/S
    Inventors: Peter Mose Larsen, Stephen J. Fey, Allan E. Karlsen, Thomas Sparre, Jorn Nerup
  • Diabetes-mediating proteins and therapeutic uses thereof
    Patent number: 7078375
    Abstract: Provided are protective and deleterious diabetes-mediating proteins and polynucleotides encoding same, transgenic animals expressing a diabetes-mediating protein, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating protein, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein.
    Type: Grant
    Filed: October 24, 1997
    Date of Patent: July 18, 2006
    Inventors: Peter Mose Larsen, Stephen J. Fey, Jorn Nerup, Allan E. Karlsen, Ulla Bjerre Christensen, Flemming Pociot, Henrik U. Andersen
  • Human diabetes-mediating proteins
    Publication number: 20060073134
    Abstract: Provided are human secreted and non-secreted diabetes mediating proteins, including protective and deleterious diabetes-mediating proteins, as well as polynucleotides encoding same, drug screening methods for identifying a test compound capable of altering the expression of a diabetes-mediating proteins, and methods of preventing or ameliorating diabetes by administering a compound capable of altering the expression of a diabetes-mediating protein.
    Type: Application
    Filed: March 20, 2003
    Publication date: April 6, 2006
    Applicant: Syddansk Universitet
    Inventors: Peter Larsen, Stephen Fey, Jorn Nerup, Allan E Karlsen
  • Cloning and expression of human islet glutamic acid decarboxylase autoantigen
    Patent number: 6025176
    Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: February 15, 2000
    Assignee: The Board of Regents of the University of Washington and ZymoGenetics, Inc.
    Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
  • Cloning and expression of human islet glutamic acid decarboxylase autoantigen
    Patent number: 5792620
    Abstract: Human pancreatic islet cell glutamic acid decarboxylase (GAD), an autoantigen involved in the development of insulin-dependent diabetes mellitus (IDDM), has been cloned, sequenced and expressed by recombinant means. Recombinant human islet cell GAD polypeptides and antibodies specific to the GAD polypeptides can be used in methods of diagnosis and treatment, including use in immunoadsorptive therapy and the induction of immune tolerance.
    Type: Grant
    Filed: August 17, 1993
    Date of Patent: August 11, 1998
    Assignees: The Board of Regents of the University of Washington, ZymoGenetics, Inc.
    Inventors: Ake Lernmark, Allan E. Karlsen, Catherine E. Grubin, William Hagopian, Patrick J. O'Hara, Donald C. Foster
  • Diagnosis of insulin-dependent diabetes
    Patent number: 5547847
    Abstract: Methods for predicting the clinical course of diabetes in patients diagnosed as having NIDDM are provided. Patients having NIDDM are tested for the presence of autoantibodies to human islet cell glutamic acid decarboxylase. Based on the presence or absence of autoantibodies, the patients are classified as to the predicted course of the disease. These methods can be used to predict the development of IDDM and to guide therapeutic intervention.
    Type: Grant
    Filed: September 7, 1993
    Date of Patent: August 20, 1996
    Assignee: University of Washington
    Inventors: William Hagopian, Ake Lernmark, Allan E. Karlsen, Mona Landin-Olsson